Methods and compositions for the treatment of cancer cachexia
US11529323B2 · kind B2 · utility
0Cited by
0References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 13, 2018 |
| Grant date | Dec 20, 2022 |
| Priority date | — |
| Expiry date | Jan 7, 2039 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P21/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
In one aspect, the disclosure relates to methods and compositions for treatment of cancer cachexia. In a further aspect, the composition is a pharmaceutical composition comprising a class I/IIB HDAC inhibitor and an androgen. In a still further aspect, the method of treatment comprises administering a class I/IIB HDAC inhibitor and an androgen to a subject or patient who has been diagnosed as having cancer cachexia. In some aspects, the class I/IIB HDAC inhibitor is a compound known as AR-42.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.